These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 10976636)

  • 1. Acetazolamide opens the muscular KCa2+ channel: a novel mechanism of action that may explain the therapeutic effect of the drug in hypokalemic periodic paralysis.
    Tricarico D; Barbieri M; Camerino DC
    Ann Neurol; 2000 Sep; 48(3):304-12. PubMed ID: 10976636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbonic anhydrase inhibitors ameliorate the symptoms of hypokalaemic periodic paralysis in rats by opening the muscular Ca2+-activated-K+ channels.
    Tricarico D; Mele A; Conte Camerino D
    Neuromuscul Disord; 2006 Jan; 16(1):39-45. PubMed ID: 16368240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of K+ conductance improves in vitro the contraction force of skeletal muscle in hypokalemic periodic paralysis.
    Grafe P; Quasthoff S; Strupp M; Lehmann-Horn F
    Muscle Nerve; 1990 May; 13(5):451-7. PubMed ID: 2345562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A case of hypokalemic periodic paralysis: utility of exercise test for the assessment of therapeutic efficacy].
    Watanabe M; Hasegawa T; Takeda A; Shiga Y; Itoyama Y
    No To Shinkei; 2003 Jun; 55(6):527-9. PubMed ID: 12884806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The biophysical and pharmacological characteristics of skeletal muscle ATP-sensitive K+ channels are modified in K+-depleted rat, an animal model of hypokalemic periodic paralysis.
    Tricarico D; Pierno S; Mallamaci R; Brigiani GS; Capriulo R; Santoro G; Camerino DC
    Mol Pharmacol; 1998 Jul; 54(1):197-206. PubMed ID: 9658206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sour on the inside, calm on the outside: how acetazolamide may stabilize membrane excitability.
    Ruff RL
    Muscle Nerve; 2006 Sep; 34(3):263-4. PubMed ID: 16810686
    [No Abstract]   [Full Text] [Related]  

  • 7. Insulin acts in hypokalemic periodic paralysis by reducing inward rectifier K+ current.
    Ruff RL
    Neurology; 1999 Oct; 53(7):1556-63. PubMed ID: 10534267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [From gene to diseases; hypokalemic periodic paralysis].
    Links TP; Ginjaar HB; van der Hoeven JH
    Ned Tijdschr Geneeskd; 2004 May; 148(21):1035-8. PubMed ID: 15185439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Speculations on hypokalemic periodic paralysis.
    Zierler KL
    Am J Med Sci; 1973 Aug; 266(2):130-3. PubMed ID: 4742367
    [No Abstract]   [Full Text] [Related]  

  • 10. Voltage-dependent antagonist/agonist actions of taurine on Ca(2+)-activated potassium channels of rat skeletal muscle fibers.
    Tricarico D; Barbieri M; Conte Camerino D
    J Pharmacol Exp Ther; 2001 Sep; 298(3):1167-71. PubMed ID: 11504816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment for periodic paralysis.
    Sansone V; Meola G; Links TP; Panzeri M; Rose MR
    Cochrane Database Syst Rev; 2008 Jan; (1):CD005045. PubMed ID: 18254068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary periodic paralyses.
    Finsterer J
    Acta Neurol Scand; 2008 Mar; 117(3):145-58. PubMed ID: 18031562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The R900S mutation in CACNA1S associated with hypokalemic periodic paralysis.
    Ke Q; He F; Lu L; Yu P; Jiang Y; Weng C; Huang H; Yi X; Qi M
    Neuromuscul Disord; 2015 Dec; 25(12):955-8. PubMed ID: 26433613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SCN4A-associated hypokalemic periodic paralysis merits a trial of acetazolamide.
    Venance SL; Jurkat-Rott K; Lehmann-Horn F; Tawil R
    Neurology; 2004 Nov; 63(10):1977. PubMed ID: 15557532
    [No Abstract]   [Full Text] [Related]  

  • 15. [Recent progress on the searchs of pathogenesis of thyrotoxic periodic paralysis].
    Shishiba Y
    Nihon Rinsho; 2006 Dec; 64(12):2339-47. PubMed ID: 17154102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acetazolamide-induced muscle weakness in hypokalemic periodic paralysis.
    Ikeda K; Iwasaki Y; Kinoshita M; Yabuki D; Igarashi O; Ichikawa Y; Satoyoshi E
    Intern Med; 2002 Sep; 41(9):743-5. PubMed ID: 12322805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyrotoxic hypokalemic periodic paralysis triggered by high carbohydrate diet.
    El-Hennawy AS; Nesa M; Mahmood AK
    Am J Ther; 2007; 14(5):499-501. PubMed ID: 17890941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of "permanent" muscle weakness in familial Hypokalemic Periodic Paralysis.
    Dalakas MC; Engel WK
    Muscle Nerve; 1983; 6(3):182-6. PubMed ID: 6855804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium channel inactivation defects are associated with acetazolamide-exacerbated hypokalemic periodic paralysis.
    Bendahhou S; Cummins TR; Griggs RC; Fu YH; Ptácek LJ
    Ann Neurol; 2001 Sep; 50(3):417-20. PubMed ID: 11558801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation screening in Korean hypokalemic periodic paralysis patients: a novel SCN4A Arg672Cys mutation.
    Kim MK; Lee SH; Park MS; Kim BC; Cho KH; Lee MC; Kim JH; Kim SM
    Neuromuscul Disord; 2004 Nov; 14(11):727-31. PubMed ID: 15482957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.